09.05.2023 20:02:05

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 9 May 2023 The execution of Novo Nordisk A/S’ overall share repurchase programme for 2023 of DKK 30 billion continues. As part of this, Novo Nordisk A/S has now initiated a new share repurchase programme of up to DKK 5.8 billion in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules”).

The purpose of the programme is to reduce the company’s share capital and to meet obligations arising from share-based incentive programmes. B shares will be repurchased during the trading period starting 10 May 2023 and ending on 8 August 2023. A maximum of 190,000,000 B shares in total can be bought during the trading period.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 57,100 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.

Contact for further information

Media: 
Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com

Natalia Salomao Abrahao (US)
+1 848 304 1027
niaa@novonordisk.com

Investors: 
Daniel Muusmann Bohsen
+45 3075 2175
dabo@novonordisk.com

Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com

David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com

Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com

Company announcement No 33 / 2023

Attachment


Analysen zu Novo Nordiskmehr Analysen

29.04.24 Novo Nordisk Neutral UBS AG
25.04.24 Novo Nordisk Overweight JP Morgan Chase & Co.
24.04.24 Novo Nordisk Outperform Bernstein Research
26.03.24 Novo Nordisk Neutral UBS AG
25.03.24 Novo Nordisk Overweight Barclays Capital
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!